By: IPP Bureau
Last updated : March 12, 2026 5:02 pm
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
Zydus Lifesciences has launched Diasens and GlucoLive, its new portfolio of AI-powered Continuous Glucose Monitoring (CGM) devices. These next-gen tools use artificial intelligence to provide real-time insights and feature integrated remote care capabilities. By connecting patients, caregivers, and doctors in a seamless closed-loop ecosystem, the system offers advanced analytics for more proactive diabetes management.
Zydus has teamed up with the health-tech firm TatvaCare to launch GoodFlip, an all-in-one mobile platform for patient care. This integrated ecosystem uses AI to analyze medical reports and offers users personalized coaching for diet and exercise, digital consultations, lab bookings, and a secure digital medical vault.
Speaking on the launch, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited, said, “The launch of Diasens and GlucoLive strengthen our companion diagnostics portfolio for chronic disease management. Focused on patient-centric convenience and better quality of life, these CGMs powered by AI technology, will give patients real-time access to key glycaemic data on their mobile devices, simplifying monitoring and control. The convergence of science, innovation, health and technology is critical for patients managing chronic diseases like diabetes, CKD, or organ transplant – offering a quick, reliable, and safe glucose monitoring solution with utmost convenience.”
According to the ICMR-INDIAB study in *The Lancet Diabetes & Endocrinology*, India faces a massive health crisis with over 101 million diabetics—the world's second-highest burden—and 136 million pre-diabetics. Diabetes drives 25–40% of Chronic Kidney Disease cases, while immunosuppressive therapy creates high demand for transplant-related diabetes management.
Despite this burden, most glucose monitoring in India remains episodic - limited to periodic finger-prick tests or laboratory HbA1c checks every three to six months. Existing CGM devices in the Indian market predominantly rely on NFC technology, requiring patients to manually scan the sensor to retrieve readings. This creates gaps in data continuity, delays clinical intervention, and places the burden of vigilance entirely on the patient.
Diasens and GlucoLive will enable automatic streaming of glucose readings to the patient’s smartphone every three minutes - without manual scanning - ensuring uninterrupted capture, including overnight reading and in emergencies.
Through TatvaCare’s GoodFlip app, AI analytics will detect trends, flags hypo-/hyperglycaemic episodes, link fluctuations to food and activity, and generate actionable insights. A clinician dashboard will support remote monitoring, early intervention, and data-driven treatment adjustments.